The strong MRD clearance data and clean safety profile de-risk the ALPHA3 trial and support confidence in cema-cel’s potential as a first-line consolidation therapy. With no serious adverse events and outpatient feasibility, this positions Allogene favorably ahead of the mid-2027 interim analysis — a key catalyst. Monitor site activation timelines and enrollment progress in new geographies.
Price Chart
Executive Summary
Allogene Therapeutics announced regulatory clearance to expand its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia, following a positive interim futility analysis showing 58.3% MRD clearance in the cema-cel arm versus 16.7% in standard of care. The trial expansion supports global development, with enrollment expected to reach ~220 patients by end-2027 and an interim event-free survival analysis anticipated in mid-2027.
Key Facts
- Regulatory authorities in South Korea and Australia have cleared expansion of the ALPHA3 Phase 2 trial for cema-cel in first-line LBCL.
- Interim futility analysis in 24 patients showed 58.3% MRD clearance with cema-cel vs. 16.7% in standard of care.
- No serious treatment-related adverse events, CRS, or ICANS were reported; no hospitalizations occurred.
- Trial expected to enroll ~220 patients globally by end of 2027, with interim EFS analysis in mid-2027 and primary analysis in mid-2028.
- Cema-cel has RMAT designation in r/r LBCL and is being studied as a potential '7th cycle' consolidation therapy post-R-CHOP.
Financial Impact
Non-immediate financial impact; potential long-term value creation if trial success leads to BLA submission and approval.
Risk Factors
- Interim data from only 24 patients may not predict final outcomes.
- MRD clearance is a surrogate endpoint; it may not translate into improved event-free or overall survival.
- Future trial execution risks in new jurisdictions could delay enrollment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.22 (−2.40%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.22 (−38.38%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.22 (−39.90%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.22 (+41.63%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.22 (−38.07%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.22 (+41.06%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.22 (+41.06%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.22 (−43.78%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.22 (−43.78%) |
May 28, 2026 21w ago | Press Release | $2.17 $2.15 | ▼ −0.92% | ▼ −1.20% | $1.22 (−43.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers